Thyroid nodule other diagnostic studies

Jump to navigation Jump to search


Thyroid nodule Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thyroid nodule from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thyroid nodule other diagnostic studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Thyroid nodule other diagnostic studies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thyroid nodule other diagnostic studies

CDC on Thyroid nodule other diagnostic studies

Thyroid nodule other diagnostic studies in the news

Blogs on Thyroid nodule other diagnostic studies

Directions to Hospitals Treating Thyroid nodule

Risk calculators and risk factors for Thyroid nodule other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Other Diagnostic Studies

Fine needle aspiration

The most important diagnostic test to differentiate thyroid nodules from each other is fine needle aspiration (FNA). As FNA is considered as an aggressive procedure, the American Thyroid Association developed the following criteria for FNA indication:

  • Nodules ≥ 1 cm with intermediate or high suspicion US pattern
  • Nodules ≥ 1.5 cm with low suspicion US pattern
  • Nodules ≥ 2 cm with very low suspicion US pattern (e.g., spongiform). Observation an alternate option
  • For nodules that do not meet the above criteria, FNA is not required, including nodules < 1 cm (with some exceptions) and purely cystic nodules 26462967

Molecular marker evaluation

The molecular marker evaluation tests are performed using samples that are collected during fine needle aspiration, from needle washings.

The most important indications of the molecular markers study include indeterminate cytological diagnosis, to assist with decision making about management option (surgical treatment). The molecular tests which have the most available data are: Afirma Gene-expression Classifier [68], seven-gene panel of genetic mutations and rearrangements [69] and galectin-3 immunohistochemistry [70].

The Afirma gene-expression classifier (167 GEC; mRNA expression of 167 genes) evaluates for the presence of benign gene expression profile. It has a high sensitivity (92 %) and negative predictive (93 %) value but low positive predictive value and specificity (48–53 %) [68, 71]. It is used as a rule out test to identify benign nodules. A benign GEC result predicts low risk of malignancy but the nodules classified as benign still have ~5 % risk of malignancy [71, 72].

The seven gene mutation and rearrangement analysis panel evaluates for BRAF, NRAS, HRAS and KRAS point mutations and common rearrangements of RET/PTC and PAX8/PPARγ. It has a high specificity (86–100 %) and positive predictive value (84–100 %) but poor sensitivity (reported from 44 to 100 %) [69, 73–75]. It is being used as a rule in test for thyroid malignancy.

References

Template:WH Template:WS